New Hope Chinese Cancer Care Foundation

NCCN: Cancer and COVID-19 Vaccination Version 1.0, January 22 https://www.nccn.org//COVID-19_Vaccination_Guidance_V1.0.p Preliminary Recommendations of the NCCN COVID-19 Vaccination Advisory Committee... * Patients with cancer should be prioritized for vaccination (CDC priority group 1b/c) and should be immunized when vaccination is available to them. * Immunization is recommended for all patients receiving active therapy, with the understanding that there are limited safety and efficacy data in these patients. * Reasons for delay of vaccines are similar to the general public (e.g., recent exposure to COVID-19), and cancer-specific factors. Vaccination should be delayed for at least 3 months following HCT or engineered cellular therapy (e.g. CAR-T cells) to maximize vaccine efficacy. * Caregivers and household/close contacts should be immunized when possible. 1) Prioritize patients with active cancer on treatment (including hematopoietic and cellular therapy), those planned to start treatment and those immediately (<6 months) post- treatment, except those receiving only hormonal therapy. 2) Consider additional risk factors for such patients and other factors linked to adverse COVID- 19 complications including but not limited to: * Patients with advanced age (e.g., 65 years of age) * Patients with co-morbidities (e.g. chronic pulmonary, cardiovascular or renal disease) * Social and demographic factors that include poverty, limited access to healthcare, and under-represented minorities

- 1/23/211000 - 11:30 AM https://us02web.zoom.us//tZcuce6sqT4sE9MVdjFr8U_QuxKhN1DCh Santa Clara Kaiser Grace Li, MD, PhD Zoom

1/19/211030 AM https://us02web.zoom.us//tZ0rdu-rqTwuGtTYbdtTTGypFXQIF1dce Helen Hou, 2001Helen Helen 18

- https://mailchi.mp/bfa44ffa20e0/2018-june-4341730

- Lillian ~ video: https://qrgo.page.link/sb1Rk